Using transcriptomic data from patients with mCRPC in the SU2C/Prostate Cancer Foundation cohort (27), we observed that Mcl-1 and Bcl-xL had higher expression than Bcl-2 (Fig. 1G), indicating that Mcl-1 and Bcl-xL are potential targets in mCRPC. This evidence concerns the gene BCL2 and prostate carcinoma.